Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015839
Chunk: 220

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 220
---
 the time of issuance. Since the market price of our common shares may fluctuate from time to time after the date of this prospectus and, as a result, the actual purchase price to be paid by the Selling Shareholder under the SEPA for common shares, if any, may also fluctuate, in order for us to receive the full amount of the Selling Shareholder’s commitment under the SEPA, it is possible that we may need to issue and sell more than the number of shares being registered for resale under the registration statement that includes this prospectus.

If it becomes necessary for us to issue and sell to the Selling Shareholder more shares than are being registered for resale under this prospectus in order to receive aggregate gross proceeds of $15,000,000 under the SEPA, we must first file with the SEC one or more additional registration statements to register under the Securities Act the resale by the Selling Shareholder of any such additional common shares, which the SEC must declare effective, in each case, before we may elect to sell any additional common shares to the Selling Shareholder under the SEPA. The number of common shares ultimately offered for resale by the Selling Shareholder depends upon the number of common shares, if any, we ultimately sell to the Selling Shareholder under the SEPA.

<div align='center'>151</div>

The issuance, if any, of common shares to the Selling Shareholder pursuant to the SEPA would not affect the rights or privileges of our existing shareholders, except that the economic and voting interests of each of our existing shareholders would be diluted. Although the number of common shares that our existing shareholders own would not decrease as a result of sales, if any, under the SEPA, the common shares owned by our existing shareholders would represent a smaller percentage of our total outstanding common shares after any such issuance.

The following table sets forth the number of common shares to be issued to the Selling Shareholder under the SEPA at varying purchase prices:

| Assumed Average 
 Purchase Price  
 Per Share       |   Number of Registered 
 Shares to be Issued if 
       Full Purchase(1) | Percentage of Outstanding  
 Shares After Giving Effect 
 to the Issuance to the     
 Selling Shareholder(2)     |       Gross Proceeds from the 
 Sale of Shares to the Selling 
         Shareholder Under the 
                          SEPA |
| $1.00           |              9,652,672 | 45.0%                      |                    $9,652,672 |
| $1.50